Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04862260
Other study ID # CHLOE pancreas
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date October 4, 2021
Est. completion date December 31, 2026

Study information

Verified date February 2024
Source CHU de Quebec-Universite Laval
Contact Anne Gangloff, MD PhD FRCPC
Phone 418-525-4444
Email anne.gangloff@crchudequebec.ulaval.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cardiovascular diseases and cancers, the two leading causes of death in Canada, require cholesterol to sustain their progression. All cells require cholesterol, but cancer cells have much higher needs to sustain growth, division and metastasis. The availability of new cholesterol-lowering drugs developed to protect patients from heart diseases has resulted in unprecedented low levels of cholesterol. The combination of atorvastatin, ezetimibe and Repatha, which are 3 cholesterol-lowering drugs used in combination, is safe, well tolerated and efficient over years of treatment. Recent reports indicate that abundant cholesterol supplies are required to sustain the progression of pancreatic ductal adenocarcinomas. This proof-of-concept study aims to verify the feasibility, the acceptability and gain preliminary data on adding a cholesterol shortage on top of FOLFIRINOX (standard chemotherapy) in newly diagnosed patients with locally advanced pancreatic adenocarcinomas or metastatic pancreatic adenocarcinomas. It is expected that a drug-induced cholesterol shortage will slow-down or stop the progression of pancreatic adenocarcinomas while increasing the response to chemotherapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date December 31, 2026
Est. primary completion date January 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: To be eligible to this trial, patients must fulfill the following inclusion criteria: 1. Have a histologically confirmed, treatment-naive locally advanced and inoperable (LaiPDAC) or metastatic pancreatic ductal adenocarcinoma (mPDAC). 2. Be at least 18 years or older at the time of signing the informed consent. 3. Have a life expectancy of at least 12 weeks. 4. Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale. 5. Have measurable disease as assessed by RECIST v1.1. 6. Agrees and amenable to a tumor (if deemed safe only) and liver biopsy (all participants) at baseline and on day 42 +/- 3 days. Patient that are anticoagulated at baseline are eligible provided it is deemed safe by the investigator to stop anticoagulation momentarily in order to safely proceed to a biopsy. 7. Eligible to standard-dose FOLFIRINOX as assessed by the principal investigator or a sub-investigator. FOLFIRINOX doses can be adapted according to SOC. 8. Demonstrate normal organ function as defined below. These assessments must be done within 7 days of Cycle 1 Day-7. Hemoglobin (Hb) = 90 g/L Absolute neutrophil count = 1.5 x 10 9/L Platelet count = 100 x 10 9/L INR = 1.3 (unless patient is anticoagulated*) aPTT = 1.5 x ULN (switching to LMWH will be recommended) Total bilirubin = 1.5 x ULN OR Direct bilirubin (for patients with total bilirubin = 1.5 x ULN) AST and ALT = 3 x ULN CPK = 1.5 x ULN Serum creatinine = 1.5 x ULN OR Estimated GFR (as per institutional standards) = 50 ml/min 9. Provide written informed consent and able to follow the trial treatment and visit schedule. 10. For Women Of Child-Bearing Potential (WOCBP), a negative serum pregnancy test must be obtained prior to receiving the study medication. 11. WOCBP should agree to use 2 different methods of birth control OR abstain from heterosexual intercourse for the duration of the trial and up to 90 days after the last study medication administration. 12. Male subjects should agree to use an adequate method of contraception for the duration of the trial and up to 90 days after the last study medication administration. Male subjects should refrain from donating sperm during this period. Exclusion Criteria: To be eligible to this trial, patients must not fulfill any of the following exclusion criteria: 1. Locally advanced pancreatic ductal adenocarcinoma deemed operable. 2. Any pancreatic ductal adenocarcinoma deemed operable or borderline operable that can be treated with neoadjuvant chemotherapy. 3. Known additional malignancy that is progressing or that requires treatment. Exceptions include basal cell carcinoma of the skin, in situ bladder or in situ cervical cancer. Other malignancy may be eligible after consultation with the promotor-investigator. 4. Spinal cord compression or brain metastases unless treated, stable and not requiring steroids for at least 4 weeks prior to the initiation of study treatment. 5. Baseline myalgia or myositis of any etiology. 6. Prior treatment with FOLFIRINOX in the adjuvant setting. 7. History of clinically significant intolerance or myositis with any statin. 8. History of clinically significant intolerance or hypersensitivity to PCSK9 inhibitors or ezetimibe. 9. Baseline grade = 2 ULN Creatine Phosphokinase (CPK) elevation. 10. Liver tumor burden that is deemed unsafe by the investigator. 11. Major surgery or procedure from which the patient has not yet recovered. 12. Any medical condition that puts the patient at high medical risk, including but not limited to active uncontrolled infection or active bleeding diathesis. 13. Any history of disease that, in the opinion of the investigator, puts liver function at risk including but not limited to autoimmune hepatitis or history of hepatitis B, hepatitis C or human immunodeficiency virus (HIV). Screening at baseline for those conditions is not required. 14. Use of any drugs that are contraindicated as per protocol and that cannot be changed or modified to an acceptable alternative. 15. Active smoker. Complete usage of tobacco must have been stopped for at least 3 months. 16. Abnormally low hematocrit, as assessed by the oncologist.

Study Design


Intervention

Drug:
Cholesterol metabolism disruption
Cholesterol metabolism disruption using a combination of atorvastatin, ezetimibe and evolocumab in metastatic pancreatic adenocarcinomas

Locations

Country Name City State
Canada CHUM Montreal Quebec
Canada CHU de Québec-Université Laval Quebec city Quebec

Sponsors (3)

Lead Sponsor Collaborator
CHU de Quebec-Universite Laval Biovalorem, Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Investigation of changes in the lipid profile induced by the addition of cholesterol-lowering drugs to FOLFIRINOX in metastatic pancreatic ductal adenocarcinomas (mPDAC) patients. Changes in Total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides using serial assessment. All measures are in mmol/L. 1 year
Other Investigation of changes in circulating apo B levels induced by the addition of cholesterol-lowering drugs to FOLFIRINOX in locally advanced or metastatic pancreatic ductal adenocarcinomas (mPDAC) patients. Changes in Apolipoprotein B (g/L) using serial assessment. 1 year
Other Investigation of changes in Apo A1 levels induced by the addition of cholesterol-lowering drugs to FOLFIRINOX in locally advanced or metastatic pancreatic ductal adenocarcinomas (mPDAC) patients. Changes in Apolipoprotein A1 (g/L) using serial assessment. 1 year
Other Investigation of changes in PCSK9 induced by the addition of cholesterol-lowering drugs to FOLFIRINOX in locally advanced or metastatic pancreatic ductal adenocarcinomas (mPDAC) patients. Changes in total, free and phosphorylated PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9, ng/L) levels using serial assessment (measured by mass spectrometry). 1 year
Other Efficacy as measured by objective response rate To obtain a preliminary assessment of the efficacy of the combination of cholesterol metabolism disruption and FOLFIRINOX: tumoral response assessment will be centrally Evaluated using RECIST v1.1. 1 year
Other Efficacy as measured by overall survival Overall Survival (OS) at 1 year 1 year
Other Efficacy as measured by progression free survival Progression Free Survival (PFS) at 1 year 1 year
Other Investigation of changes in insulin, phytosterols, ANGPTL3, ANGPTL4, ANGPTL8 and Apo C3 levels induced by the addition of cholesterol-lowering drugs to FOLFIRINOX in locally advanced or metastatic pancreatic ductal adenocarcinomas (mPDAC) patients. Changes in insulin, phytosterols, ANGPTL3, ANGPTL4, ANGPTL8 and Apo C3 levels 1 year
Other To explore the feasibility of a larger multicenter trial Collect preliminary data permitting to obtain estimates for the feasibility of a larger multicenter trial :
Recruitment time Retention and dropout rates Acceptability of the regimen as assessed by patients Dose-limiting toxicities Response of biomarkers RECIST assessment Estimates for overall response rate (ORR) Estimates of progression-free survival (PFS) at 1 year Estimates of median overall survival (mOS) Monitor adverse effects Identification of missing data Identification of barriers to study completion Estimates to guide samples size / power calculation for a larger multicenter trial
1 year
Primary Safety as measured by the rate of adverse events To determine causality and grading severity of each adverse event (AEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2 years
Primary Characterization of dose-limiting toxicities To determine the dose at which no more than 1 out of 6 patients experience a drug related dose-limiting toxicity. To confirm that the combination of daily atorvastatin 40 mg, ezetimibe 10 mg twice daily and monthly evolocumab 420 mg meets the criterion to be the recommended phase II dose (RP2D). 2 years
Secondary LDLR (low-density lipoprotein receptor) tumoral and hepatic changes in response to the multipathway cholesterol embargo. Assessment of the level of LDLR in the tumor (hepatic metastasis ) and the liver by immunohistochemistry. 1 year
Secondary LRP1 (Low-density lipoprotein Receptor-Related Protein 1) tumoral and hepatic changes in response to the multipathway cholesterol embargo. Assessment of the level of LRP1 in the tumor (hepatic metastasis ) and the liver by immunohistochemistry. 1 year
Secondary NPC1L1 (Niemann-Pick C1-Like 1 protein) tumoral and hepatic changes in response to the multipathway cholesterol embargo. Assessment of the level of NPC1L1 in the tumor (hepatic metastasis ) and the liver by immunohistochemistry. 1 year
Secondary SRB1 (Scavenger Receptor class B type 1) tumoral and hepatic changes in response to the multipathway cholesterol embargo. Assessment of the level of SRB1 in the tumor (hepatic metastasis ) and the liver by immunohistochemistry. 1 year
Secondary MHC-1 (Major Histocompatibility Complex class 1) tumoral and hepatic changes in response to the multipathway cholesterol embargo. Assessment of the level of MHC-1 in the tumor (hepatic metastasis ) and the liver by immunohistochemistry 1 year
Secondary PD-L1 (Programmed Death-Ligand-1) changes in response to the multipathway cholesterol embargo. Assessment of the level of PD-L1 (Programmed Death-Ligand-1) in the tumor (hepatic metastasis ) and the liver by immunohistochemistry. 1 year
Secondary Change in tumoral and hepatic levels of TILs (Tumor-Infiltrating Lymphocytes) Assessment of tumoral and hepatic levels of TILs by immunohistochemistry 1 year
Secondary CD36 (Cluster of Differentiation 36) changes in response to the multipathway cholesterol embargo Assessment of tumoral and hepatic levels in the tumor (hepatic metastasis ) and the liver by immunohistochemistry. 1 year
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study